Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
That’s his son’s ID
How is that? The ID was just created today.
Tangerine is a legend here!!
Final judgement?
I believe there are 2 cases against Accord. This is one of them.
Are we sure oct 7 is still happening?
:23-cv-22221-KMW-AMD Document 24-2 Filed 09/24/24 Page 3 of 3 PageID: 1833 (2) that in view of the Court’s rulings that the asserted claims of the ’908 patent are invalid, judgment is granted in favor of Defendant on each of Plaintiffs’ claims of patent infringement with respect to that patent; and (3) pursuant to entry of this Final Judgment, all other claims and counterclaims shall be dismissed without prejudice as moot, subject to reinstatement upon reversal or remand. IT IS SO ORDERED SIGNED this 9th day of September, 2024 _________________________ WILLIAM C. BRYSON UNITED STATES CIRCUIT JUDGE
The next 6-8 weeks may be the most crucial for shareholders here both new and old Obviously the decision on the appeal of Judge Bryson's decision in favor of Accord which will be argued of October 7, will have huge ramifications in the Purdue v. Elite patent infringement claim. I would expect the Circuit Court of Appeal to make a decision sometime in early November. Should, as many expect, it be in favor of Accord, the Elite attorneys may make a motion to dismiss Purdue's claim as moot having caused a collateral estoppel of the claim involving the same issue in Accord which deemed the patent valid. Needle mover 1 will be closer to fulfillment.
I also believe that the PDUFA date for Vyvanse will be circa November 20. A positive decision will generate Needle Mover 2 with the company indicating it is ready to do a launch as early as sometime in December.
Also in November if is likely that the FDA and DEA will certify the new storage facility which will free up massive space in the production facility to produce, more Adderall, Vyvanse, Methotrexate, and Tylenol with Codeine.
Finally. in mid November there will be the conference call for the 2nd quarter.
Investors here are likely to have a lot to be thankful for as Thanksgiving ends the month.
He says that in one place they say they will wait for the other trial to complete but then underneath there is what I pasted here.
Looks like final judgement
Not sure if I did this right on this message board..
FOR THE DISTRICT OF DELAWARE PURDUE PHARMA L.P. and PURDUE PHARMACEUTICALS L.P., Plaintiffs, v. ACCORD HEALTHCARE INC., Defendant. Civil Action No. 22-913-WCB § § § § § § § § § § § FINAL JUDGMENT WHEREAS this patent infringement action was brought by Purdue Pharma L.P. and Purdue Pharmaceuticals L.P. (“Plaintiffs”) alleging, inter alia, that the filing of Abbreviated New Drug Application (“ANDA) No. 213564 by Accord Healthcare Inc. (“Defendant”) infringed U.S. Patent No. 11,304,908 (“the ’908 patent”), Dkt. No. 1; WHEREAS this matter came before the Court for a bench trial to resolve the questions of whether claims 1, 10, 18, 23, 28, and 29 of the ’908 patent are invalid for obviousness; WHEREAS the Court held a bench trial in the above-captioned action the week of February 12, 2024; WHEREAS the Court issued an opinion setting forth its findings of fact and conclusions of law on September 9, 2024. IT
IS HEREBY ORDERED AND ADJUDGED: (1) that claims 1, 10, 18, 23, 28, and 29 of the ’908 patent are declared to be invalid on the ground of obviousness, under 35 U.S.C. § 103;
ase 1:23-cv-22221-KMW-AMD Document 24-2 Filed 09/24/24 Page 3 of 3 PageID: 1833 (2) that in view of the Court’s rulings that the asserted claims of the ’908 patent are invalid, judgment is granted in favor of Defendant on each of Plaintiffs’ claims of patent infringement with respect to that patent; and (3) pursuant to entry of this Final Judgment, all other claims and counterclaims shall be dismissed without prejudice as moot, subject to reinstatement upon reversal or remand. IT IS SO ORDERED SIGNED this 9th day of September, 2024 _________________________ WILLIAM C. BRYSON UNITED STATES CIRCUIT JUDGE
I have someone with Pacer that saw it and will send it to me shortly
Hi, great company here. There is a filing in Pacer that also says it has been dismissed...if someone knows
Exhibit A - Findings of Fact,
In an intellectual property (IP) infringement case, "Exhibit A - Findings of Fact" refers to a document submitted to the court as evidence, labeled as "Exhibit A", which outlines the key factual determinations made by the judge or jury regarding the alleged infringement, essentially summarizing the critical points of evidence that support the decision in the case.
Exhibit B - Final Judgment,
A "Final Judgment" in an intellectual property (IP) infringement case refers to the court's final decision that resolves all issues in dispute, including whether infringement occurred and what remedies will be awarded, effectively ending the legal proceedings and leaving only the option to appeal to a higher court; it essentially means the court has reached its conclusive decision on the case and the parties' rights regarding the alleged infringement are now legally established.
Exhibit C - Stipulation
In an intellectual property (IP) infringement case, a stipulation is a written agreement between opposing parties that can be used to simplify the case and streamline litigation. Stipulations can be used for a variety of purposes, including: admitting facts, authenticating trial exhibits, handling confidential information, waiving the right to a jury trial, and withdrawing pending motions during settlement discussions.
This is referencing the Purdue vs. Accord case.
What are the stages of IP litigation?
– Phase I: Filing of the complaint to the case management conference. – Phase II: Scheduling conference to claim construction hearing. – Phase III: Claim construction hearing to end of expert discovery. – Phase IV: Pre-trial and Trial.
Lawsuit summary info 9/24/2024:
We write on behalf of Plaintiffs Purdue Pharma L.P., Purdue Pharmaceuticals L.P., and Rhodes Technologies (collectively, "Purdue") and Defendants Elite Laboratories, Inc. and Elite Pharmaceuticals, Inc. (collectively, "Elite") as directed by the Stipulation and Order to Extend Stay of All Proceedings (ECF Nos. 21, 23), to inform the Court of the resolution of the Accord Il case and status of the Accord I appeal.
On September 9, 2024, U.S. Circuit Judge William C. Bryson (sitting by designation in the U.S. District Court for the District of Delaware) found invalid all of the claims asserted in Purdue Pharma L.P. et al. V. Accord Healthcare Inc., Civil Action No. 22-913-WCB (D. Del.) ("the Accord I| case"). A copy of Judge Bryson's Findings of Fact and Conclusions of Law is attached as Exhibit A; a copy of the Final Judgment is attached as Exhibit B.
Independently, the U.S. Court of Appeals for the Federal Circuit has scheduled oral argument in Purdue Pharma L.P. et al. v. Accord Healthcare Inc., Case No. No. 23-1953 (Fed.Cir.) ("the Accord I appeal") for October 7, 2024.
Given the impending oral argument in the Accord I appeal, Purdue and Elite agree that the stipulated stay currently in effect should remain in place according to its existing terms until a decision is rendered in the Accord I appeal.
The parties further agree that they should provide a joint report to the Court within fifteen days of a decision in the Accord I appeal. In the joint report they will: (1) respectfully request that the stay be lifted and (2) so that the they may have the guidance of the Court and to make the most efficient use of the Court's and the parties' resources, propose a briefing schedule on the collateral estoppel effect of the Accord Il case and the Accord I appeal.
Couldn't help myself, I am on full, but you are right, not too far down the road the 100K I picked up today will seem a bargain!!!!
OK Pharma, But just reading, it says Anania found a fact, and the fact is that Purdue lost the patents, and now Elite wants a final
judgment
is that to street ?
This is correct. It's a different appeal. Didn't see this additional case. This one started a year ago and arguments are October 7th.
I'm taking the bar exam when I'm rich. Lol. I am married to an ex paralegal if that counts.
Here is the info.
I peaked through the docs and it's similar to the other. There is a second party here too. Rhodes technologies. It's two against Accord. They already lost. I imagine it will follow the same path as the other.
NOTICE OF ORAL ARGUMENT. Panel: 2410G. Case scheduled October 7, 2024. Response to Notice of Oral Argument due: 09/04/2024. Please review the attached Notice. The response to notice of oral argument form can be found here. The Oral Argument Guide can be found here. Service as of this date by the Clerk of Court. [1026782] [MJL] [Entered: 08/21/2024 03:35 PM]
Original Case: 1:20-cv-01362
Federal Circuit U.S. Court of Appeals
Case #: 0:23-cvpri-01953
Type civil private
Nature of Suit 835 Property Rights - Patent – Abbreviated New Drug Application
Case Filed: May 30, 2023
Ok is a request to continue the stay until the appeals court rules on accord trial. Oral arguments scheduled for Oct 7
Could be, I think in this case the judge is open to new revelations, like Purdue losing the patent protections,
they don’t have to wait till Feb. 25
Thank you for the explanation. Any other info would be really appreciated but thank you.
I'd guess anania (elite atty) is asking for dismissal of purdue case based on the document titles
I don’t know, its behind a pay wall,
So what’s the final judgement ?
There has been some movement on the trial
https://www.pacermonitor.com/public/case/51356241/PURDUE_PHARMA_LP_et_al_v_ELITE_LABORATORIES_INC,_et_al
Numerous trades at 6 decimals again, 0.388405 trade just a bit ago. ELTP has been popping up at lease a nickel after trading like this for a few days.
I would tell him that $.40 is still a good entry point.
Taking the fifth.
What would be your advise to a former Elite's investor who sold too soon (15 cents) and the only thing he has left is his opinions ?
Wise investors will load up on anything under $.40. This is going to take off.. You don’t wanna miss your chance to get the last of the .30s.
ELTP..................... It's a real powerhouse. LLLLLLEEEEEEEEEET's GOOOOOOOOOOooooooooo!!!!!!
Investors buying in at these prices >.39 is far from cheap and the stock is very speculative. In my viewpoint, spending 100k in cash for 256k shares is a huge investment and I wouldn't have the stomach to pull the trigger. The risk/reward ratio is great, and it takes a lot of guts or knowledge in the medical field.
I believe Jammy32 wish he didn't sell all of his shares and regret the move to this day. I currently own shares of eltp, have sold and bought shares to this point. There will be a lot of news coming out within the year 2024/2025 and I'm keeping my finger cross for the positive outcome going forward. Good luck to all the old and new investors.
So it's true. Bears are those that missed the ride 😂
I was asked to keep it private. Smart investors obviously. Go elite.
Who asked ??
$5
So many people asked me to come back for my business like opinions , not all the rah rah stuff. Go Elite
And 100 by end of year. Wow. We just won the lottery. End of what year is always the question
Doesn’t “mirage” = false vision ?
Can you work your magic and bring it to .18 again? 😋
Just another fool pumper with nothing to back up his predictions
Doubt it, but will keep heading north.
Your optics are terrible. I thought you were retiring from the board????.......AGAIN
I know. Soon
Because it’s later. Soon. Waiting. About to get real. Go Elite
Why October 10? Anything expected?
Hope everyone got what they needed because we about to hit the dollar October 10th
Firstrade is up to date to the second
You gotta be right eventually you have been saying that for at least 8 years
$3 $5 buyout
1. Methotrexate $63.4M
2. Tylenol with Codeine $43M
3. Percocet $500M
4. Norco$477M
5. Methadone 30M
6. Vyvanse$5.10 Billion
7. Dopamine Agonist $12M
8. OxyContin $720M
9. Concerta $1.16 Billion
Followers
|
1004
|
Posters
|
|
Posts (Today)
|
71
|
Posts (Total)
|
409637
|
Created
|
03/24/09
|
Type
|
Free
|
Moderators jimr1717 mrwrn2010 NASDAQ2020 IB_ namtae Dr JoeBarducci |
Senior Moderator: IB_
Posted: 7/02/2024
________________________________________________________________________________________________________________
Elite Pharmaceuticals, Inc. |
Website | Location | Employees | Facility | CEO |
www.elitepharma.com | Northvale, New Jersey | 64 | 85,000 sq ft | Nasrat Hakim |
Products & Pipeline | ||||
Drug | Market Size | Status | Competitors | Marketed By |
Adderall IR | 389.8 M | On Market | 15 | Elite |
Adderall XR | 1.56 B | On Market | 10 | Elite & Prasco |
Dantrolene | 6.3 M | On Market | 2 | Elite |
Isradipine | 5.5 M | On Market | 1 | Elite |
Loxapine | 5 M | On Market | 2 | Elite |
Phendimetrazine | 4.5 M | On Market | 4 | Elite |
Trimipramine | 2 M | On Market | 1 | Elite |
Naltrexone | 16 M | On Market | 5 | Precision Dose |
Phentermine Capsules | 7.5 M | On Market | 6 | Precision Dose |
Phentermine Tablets | 40 M | On Market | 8 | Precision Dose |
Vigabatrin | 233.7 M | On Market | 13 | Pyros |
Doxycycline | 85 M | Approved (Discontinued) | 9 | ---------- |
Tylenol with Codeine | 45 M | Approved in Launch Queue | 5 | ---------- |
Dopamine Agonist | 12 M | Filed with FDA - 22 Dec 2022 | ---------- | ---------- |
Methotrexate | 63.4M | On Market | 8 | Elite |
Percocet | 500 M | Approved in Launch Queue | 14 | ---------- |
Norco | 477 M | Approved in Launch Queue | 12 | ---------- |
Methadone | 30 M | Approved in Launch Queue | 8 | ---------- |
OxyContin | 720 M | Filed with FDA - 17 Aug 2023 | ??? | ---------- |
Vyvanse | 5.10 B | Filed with FDA - 21 Dec 2023 | 11 | ---------- |
Concerta | 1.16 B | In Development (Final Stages) | 8 | ---------- |
Financials | ||||
Fiscal Year | Revenue | Change | Net Income | Change |
2019 | 7,568,508 | ---------- | (9,279,321) | ---------- |
2020 | 17,994,639 | +137.76% | (2,240,351) | +75.86% |
2021 | 25,380,749 | +41.05% | 5,088,421 | +327.13% |
2022 | 32,262,117 | +27.11% | 8,898,245 | +74.87% |
2023 | 34,155,114 | +5.87% | 3,561,846 | -59.97% |
2024 | 56,625,128 | +65.79% | 20,108,631 | +464.56% |
2025 Q-1 | 18,803,063 | +109.39% | 3,864,056 | +144.00% |
2025 Q-2 | ||||
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |